oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-257Research ArticleОБЗОРЫREVIEWSМЕТОДЫ ЯДЕРНОЙ МЕДИЦИНЫ В ДИАГНОСТИКЕ НЕЙРОЭНДОКРИНЫХ ОПУХОЛЕЙNuclear medicine technology for diagnosisof neuroendocrine tumorsРыжковаД. В.RyzhkovaD. V.d_ryjkova@mail.ruТихоноваД. Н.ТikhonovaD. N.ГриневаЕ. Н.GrinevaE. N.ФГБУ «Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияV.A. Almazov Federal Heart, Blood and Endocrinology Centre, St-PetersburgRussian Federation201325022016165663Copyright © Рыжкова Д.В., Тихонова Д.Н., Гринева Е.Н., 20162016Рыжкова Д.В., Тихонова Д.Н., Гринева Е.Н.Ryzhkova D.V., Тikhonova D.N., Grineva E.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/257

Обзор литературы посвящен анализу радиофармацевтических препаратов (РФП) и современных радиоизотопных технологий для диагностики, стадирования и оценки прогноза при нейроэндокринных опухолях различных локализаций. На основании результатов клинических исследований продемонстрированы диагностические возможности сцинтиграфии и позитронной эмиссионной томографии (ПЭТ) при карциноидах кишки, поджелудочной железы и легких, медуллярном раке щитовидной железы, феохромоцитоме и параганглиоме и обоснован выбор РФП. Перечислены причины ложноположительных и ложноотрицательных результатов сцинтиграфии и ПЭТ.

This article is the review of issues of the literature for the past 10 years and is dedicated to the analysis of the radiopharmaceuticals and efficacy of the novel nuclear medicine technologies for the diagnosis, staging and prognosis of neuroendocrine tumors. Diagnostic efficacy of a scintigraphy and a positron emission tomography for detection of gastroenteropancreatic and lung carcinoid, medullary thyroid cancer, pheochromocytoma and haraganglioma and choice of radiopharmaceuticals were demonstrated by the results of the clinical studies. The causes of false positive and falce negative results were specified.

сцинтиграфия с мечеными лигандами к соматостатиновым рецепторампозитронная эмиссионная томографиянейроэндокринные опухоли18F-ДОПА68Ga-DOTA-пептидыsomatostatin receptor scintigraphypositron emission tomographyneuroendocrine tumors18F-DOPA68Ga-DOTA-peptidesReferencesАфанасьев С.Г., Авдеев С.В., Пак А.В. и др. Опыт лечения АКТГ-эктопированной опухоли легкого//Сибирский онкологический журнал. 2009. № 6 (36). С. 83-86Афанасьев С.Г., Авдеев С.В., Пак А.В. и др. Опыт лечения АКТГ-эктопированной опухоли легкого//Сибирский онкологический журнал. 2009. № 6 (36). С. 83-86Егоров А.В., Кузин Н.М. Вопросы диагностики нейроэндокринных опухолей поджелудочной железы//Практическая онкология. 2005. Т. 6, № 4. С. 206-212Егоров А.В., Кузин Н.М. Вопросы диагностики нейроэндокринных опухолей поджелудочной железы//Практическая онкология. 2005. Т. 6, № 4. С. 206-212Имянитов Е.Н. Эпидемиология и биология нейроэндокринных опухолей//Практическая онкология. 2005. Т. 6, № 4. С. 202-205Имянитов Е.Н. Эпидемиология и биология нейроэндокринных опухолей//Практическая онкология. 2005. Т. 6, № 4. С. 202-205Ларенков А.А., Кодина Г.Е., Брускин А.Б. Радионуклиды галлия в ядерной медицине: радиофармацевтические препараты на основе изотопа 68Ga//Медицинская радиология и радиационная безопасность. 2011. Т. 56, № 5. С. 56-73Ларенков А.А., Кодина Г.Е., Брускин А.Б. Радионуклиды галлия в ядерной медицине: радиофармацевтические препараты на основе изотопа 68Ga//Медицинская радиология и радиационная безопасность. 2011. Т. 56, № 5. С. 56-73Латыпов В.Р., Попов О.С., Вусик А.Н., Латыпова В.Н., Гейдаров Р.Я. Особенности и результаты хирургического лечения пациентов с опухолями надпочечников//Сибирский онкологический журнал. 2010. № 1 (37). С. 56-60Латыпов В.Р., Попов О.С., Вусик А.Н., Латыпова В.Н., Гейдаров Р.Я. Особенности и результаты хирургического лечения пациентов с опухолями надпочечников//Сибирский онкологический журнал. 2010. № 1 (37). С. 56-60Ширяев С.В. Эмиссионная томография в комплексной диагностике опухолевых поражений печени: Автореф. дис. … д-ра мед. наук. М., 2009. 23 сШиряев С.В. Эмиссионная томография в комплексной диагностике опухолевых поражений печени: Автореф. дис. … д-ра мед. наук. М., 2009. 23 сAhlstroem H., Eriksson B., Bergstroem M. et al. Pancreatic neuroendocrine tumours: Diagnosis with PET//Radiology. 1995. Vol. 195. P. 333-337Ahlstroem H., Eriksson B., Bergstroem M. et al. Pancreatic neuroendocrine tumours: Diagnosis with PET//Radiology. 1995. Vol. 195. P. 333-337Alexander K., Putzer D., Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine//Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. P. 865-887Alexander K., Putzer D., Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine//Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. P. 865-887Ambrosini V., Tomassetti P., Castellucci P. et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-enteropancreatic and lung neuro-endocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 1431-1438Ambrosini V., Tomassetti P., Castellucci P. et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-enteropancreatic and lung neuro-endocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 1431-1438Antunes P., Ginj M., Zhang H. et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals//Eur. J. Nucl. Med. Mol. Imaging. 2007. Vol. 34. P. 982-993Antunes P., Ginj M., Zhang H. et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals//Eur. J. Nucl. Med. Mol. Imaging. 2007. Vol. 34. P. 982-993Bansal R., Tierney W., Carpenter S. et al. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors//Gastrointest. Endoscop. 1999. Vol. 49 (1). P. 19-25Bansal R., Tierney W., Carpenter S. et al. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors//Gastrointest. Endoscop. 1999. Vol. 49 (1). P. 19-25Beheshti M., Pеocher S., Vali R. et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT//Eur. Radiol. 2009. Vol. 19. P. 1425-1434Beheshti M., Pеocher S., Vali R. et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT//Eur. Radiol. 2009. Vol. 19. P. 1425-1434Binderup T., Knigge U., Loft A., Federspiel B. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors//Clin. Cancer Res. 2010. Vol. 16 (3). P. 978-985Binderup T., Knigge U., Loft A., Federspiel B. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors//Clin. Cancer Res. 2010. Vol. 16 (3). P. 978-985Esser J.P., Krenning E.P., Teunissen J.J. et al. Comparison of [(177) Lu-DOTA(0),Tyr (3)]octreotate and [(177)Lu-DOTA(0),Tyr (3)]octreotide: which peptide is preferable for PRRT?//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 1346-1351Esser J.P., Krenning E.P., Teunissen J.J. et al. Comparison of [(177) Lu-DOTA(0),Tyr (3)]octreotate and [(177)Lu-DOTA(0),Tyr (3)]octreotide: which peptide is preferable for PRRT?//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 1346-1351Ezziddin S., Logvinski T., Yong-Hing C. et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors//J. Nucl. Med. 2006. Vol. 47. P. 223-233Ezziddin S., Logvinski T., Yong-Hing C. et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors//J. Nucl. Med. 2006. Vol. 47. P. 223-233Fanti S., Ambrosini V., Tomassetti P. et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET//Biomed. Pharmacother. 2008. Vol. 62. P. 667-671Fanti S., Ambrosini V., Tomassetti P. et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET//Biomed. Pharmacother. 2008. Vol. 62. P. 667-671Frilling A., Sotiropoulos G.C., Radtke A. et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors//Ann. Surg. 2010. Vol. 252. P. 850-856Frilling A., Sotiropoulos G.C., Radtke A. et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors//Ann. Surg. 2010. Vol. 252. P. 850-856Gabriel M., Decristoforo C., Kendler D. et al. 68Ga-DOTA-Tyr3octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT//J. Nucl. Med. 2007. Vol. 48. P. 508-518Gabriel M., Decristoforo C., Kendler D. et al. 68Ga-DOTA-Tyr3octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT//J. Nucl. Med. 2007. Vol. 48. P. 508-518Gibril F., Curtis L.T., Termanini B. et al. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome//Gastroenterology. 1997. Vol. 112 (2). P. 567-574Gibril F., Curtis L.T., Termanini B. et al. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome//Gastroenterology. 1997. Vol. 112 (2). P. 567-574Gibril F., Reynolds J.C., Doppman J.L. et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastaticgastrinomas//Ann. Intern. Med. 1996. Vol. 125. P. 26-34Gibril F., Reynolds J.C., Doppman J.L. et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastaticgastrinomas//Ann. Intern. Med. 1996. Vol. 125. P. 26-34Haug A., Auernhammer C.J., Wängler B. et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 36. P. 765-770Haug A., Auernhammer C.J., Wängler B. et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 36. P. 765-770Hofmann M., Maecke H., Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data//Eur. J. Nucl. Med. 2001. Vol. 28. P. 1751-1757Hofmann M., Maecke H., Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data//Eur. J. Nucl. Med. 2001. Vol. 28. P. 1751-1757Imani F., Agopian V.G., Auerbach M.S. et al. 18F-FDOPAPET and PET/CT accurately localize pheochromocytomas//J. Nucl. Med. 2009. Vol. 50. P. 513-519Imani F., Agopian V.G., Auerbach M.S. et al. 18F-FDOPAPET and PET/CT accurately localize pheochromocytomas//J. Nucl. Med. 2009. Vol. 50. P. 513-519Jacobson A.F., Deng H., Lombard J. et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis//J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 2596-2606Jacobson A.F., Deng H., Lombard J. et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis//J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 2596-2606Jager P., Chirakal R., Marriott C.J. et al. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications//J. Nucl. Med. 2008. Vol. 49. P. 573-586Jager P., Chirakal R., Marriott C.J. et al. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications//J. Nucl. Med. 2008. Vol. 49. P. 573-586Jindal T., Kumar A., Venkitaraman B. et al. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids//Korean J. Intern. Med. 2010. Vol. 25. P. 386-391Jindal T., Kumar A., Venkitaraman B. et al. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids//Korean J. Intern. Med. 2010. Vol. 25. P. 386-391Kaltsas G., Korbonits M., Heintz E. et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors//J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 895-902Kaltsas G., Korbonits M., Heintz E. et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors//J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 895-902Katlas G.A., Mukherjee J.J., Grossman A.B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours//Ann. Oncol. 2001. Vol. 12. Suppl. 2. S. 47-50Katlas G.A., Mukherjee J.J., Grossman A.B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours//Ann. Oncol. 2001. Vol. 12. Suppl. 2. S. 47-50Kauhanen S., Seppanen M., Minn H. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or b-cell hyperplasia in adult patients//J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 1237-1244Kauhanen S., Seppanen M., Minn H. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or b-cell hyperplasia in adult patients//J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 1237-1244Kauhanen S., Seppaеnen M., Ovaska J. et al. The clinical value of [18F] fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors//Endocr. Relat. Cancer. 2009. Vol. 16. P. 255-265Kauhanen S., Seppaеnen M., Ovaska J. et al. The clinical value of [18F] fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors//Endocr. Relat. Cancer. 2009. Vol. 16. P. 255-265Koopmans K.P., de Groot J.W., Plukker J.T. et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation//J. Nucl. Med. 2008. Vol. 49. P. 524-531Koopmans K.P., de Groot J.W., Plukker J.T. et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation//J. Nucl. Med. 2008. Vol. 49. P. 524-531Koopmans K.P., Neels O.C., Kema I.P. et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenylalanine and 11C-5-hydroxy-tryptophan positron emission tomography//J. Clin. Oncol. 2008. Vol. 26. P. 1489-1495Koopmans K.P., Neels O.C., Kema I.P. et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenylalanine and 11C-5-hydroxy-tryptophan positron emission tomography//J. Clin. Oncol. 2008. Vol. 26. P. 1489-1495Koukouraki S., Strauss L.G., Georgoulias V. et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 460-466Koukouraki S., Strauss L.G., Georgoulias V. et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 460-466Kowalski J., Henze M., Schuhmacher J. et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors//Mol. Imaging Biol. 2003. Vol. 5. P. 42-48Kowalski J., Henze M., Schuhmacher J. et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors//Mol. Imaging Biol. 2003. Vol. 5. P. 42-48Kwekkeboom D., Krenning E.P., de Jong M. Peptide receptor imaging and therapy//J. Nucl. Med. 2000. Vol. 41. P. 1704-1713Kwekkeboom D., Krenning E.P., de Jong M. Peptide receptor imaging and therapy//J. Nucl. Med. 2000. Vol. 41. P. 1704-1713Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors//J. Clin. Oncol. 2005. Vol. 23. P. 2754-2762Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors//J. Clin. Oncol. 2005. Vol. 23. P. 2754-2762Lebtahi R., Cadiot G., Sarda L. et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors//J. Nucl. Med. 1997. Vol. 6. P. 853-858Lebtahi R., Cadiot G., Sarda L. et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors//J. Nucl. Med. 1997. Vol. 6. P. 853-858McEwan A.J., Shapiro B., Sisson J.C. et al. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors//Semin. Nucl. Med. 1985. Vol. 15. P. 132-153McEwan A.J., Shapiro B., Sisson J.C. et al. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors//Semin. Nucl. Med. 1985. Vol. 15. P. 132-153Minn H., Kauhanen S., Seppaenen M. et al. 18F-FDOPA: A Multiple-Target Molecule//J. Nucl. Med. 2009. Vol. 50. P. 1915-1918Minn H., Kauhanen S., Seppaenen M. et al. 18F-FDOPA: A Multiple-Target Molecule//J. Nucl. Med. 2009. Vol. 50. P. 1915-1918Mohnike K., Blankenstein O., Minn H. et al. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism//Horm. Res. 2008. Vol. 70. P. 65-72Mohnike K., Blankenstein O., Minn H. et al. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism//Horm. Res. 2008. Vol. 70. P. 65-72Nielsen J.T., Nielsen B.V., Rehling M. Location of adrenal medullary pheochromocytoma by I-123-metaiodobenzylguanidine SPECT//Clin. Nucl. Med. 1996. Vol. 21. P. 695-699Nielsen J.T., Nielsen B.V., Rehling M. Location of adrenal medullary pheochromocytoma by I-123-metaiodobenzylguanidine SPECT//Clin. Nucl. Med. 1996. Vol. 21. P. 695-699Orlefors H., Sundin A., Ahlstrоm H. et al. Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors//J. Clin. Oncol. 1998. Vol. 16. P. 2534-2542Orlefors H., Sundin A., Ahlstrоm H. et al. Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors//J. Clin. Oncol. 1998. Vol. 16. P. 2534-2542Orlefors H., Sundin A., Garske U. et al. Whole-body (11)C-5hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin recep tor scintigraphy and computed tomography//J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 3392-3400Orlefors H., Sundin A., Garske U. et al. Whole-body (11)C-5hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin recep tor scintigraphy and computed tomography//J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 3392-3400Prasad V., Ambrosini V., Hommann M. et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT//Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 67-77Prasad V., Ambrosini V., Hommann M. et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT//Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 67-77Putzer D., Gabriel M., Henninger B. et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy//J. Nucl. Med. 2009. Vol. 50. P. 1214-1221Putzer D., Gabriel M., Henninger B. et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy//J. Nucl. Med. 2009. Vol. 50. P. 1214-1221Raber M.N., Faintuch J., Abbruzzese J.L. et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastaticcarcinomaof unknownprimaryorigin//Ann.Oncol.1991. Vol. 2. P. 519-520Raber M.N., Faintuch J., Abbruzzese J.L. et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastaticcarcinomaof unknownprimaryorigin//Ann.Oncol.1991. Vol. 2. P. 519-520Srirajaskanthan R., Kayani I., Quigley A.M. The Role of 68GaDOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy//J. Nucl. Med. 2010. Vol. 51. P. 875-882Srirajaskanthan R., Kayani I., Quigley A.M. The Role of 68GaDOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy//J. Nucl. Med. 2010. Vol. 51. P. 875-882Sundin А. Nuclear imaging of neuroendocrine tumours//Best Pract. Res. Clin. Endocrinol. Metab. 2007. Vol. 21 (1). P. 69-85Sundin А. Nuclear imaging of neuroendocrine tumours//Best Pract. Res. Clin. Endocrinol. Metab. 2007. Vol. 21 (1). P. 69-85Taieb D., Tessonnier L., Sebag F. et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas//Clin. Endocrin. (Oxf). 2008. Vol. 69. P. 580-586Taieb D., Tessonnier L., Sebag F. et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas//Clin. Endocrin. (Oxf). 2008. Vol. 69. P. 580-586Termanini B., Gibil F., Reynolds J.C. et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management//Gastroenterology. 1997. Vol. 112. P. 335-347Termanini B., Gibil F., Reynolds J.C. et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management//Gastroenterology. 1997. Vol. 112. P. 335-347Treglia G., Castaldi P., Rindi G. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis//Endocrine. 2012. Vol. 42. P. 80-87Treglia G., Castaldi P., Rindi G. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis//Endocrine. 2012. Vol. 42. P. 80-87Wiseman G.A., Pacak K., O’Dorisio M.S. et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial//J. Nucl. Med. 2009. Vol. 50. P. 1448-1454Wiseman G.A., Pacak K., O’Dorisio M.S. et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial//J. Nucl. Med. 2009. Vol. 50. P. 1448-1454

The authors declare that there are no conflicts of interest present.